《大行報告》中銀國際降信義光能(00968.HK)及福萊特玻璃(06865.HK)評級至「沽售」 下調目標價
中銀國際發表報告,認為與盈利增長減速相比,領先的太陽能玻璃製造商的估值過高,將信義光能(00968.HK)及福萊特玻璃(06865.HK)評級由「持有」降至「沽售」,將信義光能目標價由15.4元下調至11.2元,福萊特玻璃目標價由30.5元下調至25.3元。
中銀國際表示,雖然部分人可能會認為不斷上漲的太陽能玻璃銷售均價是一個觸底信號,但該行認為最差的情況尚未到來,太陽能玻璃行業已進入不可逆轉的產能過剩困境,成本曲線快速趨平將導致龍頭企業利潤率溢價惡化。
中銀國際相信,短期內來自各方面的成本壓力可能會加劇並對毛利率和市場情緒造成壓力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.